{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:45:10Z","timestamp":1788839110002,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018854","name":"Sirtex Medical Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejrad.2023.111120","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:27:02Z","timestamp":1695936422000},"page":"111120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Osman","family":"\u00d6cal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Johannes","family":"Zech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"van Delden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer Reha","family":"\u00dcm\u00fctl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib Ben","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Narciso","family":"De Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Phuong Thao","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aghdassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejrad.2023.111120_b0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2011.06947.x","article-title":"Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis","volume":"27","author":"Li","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejrad.2023.111120_b0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Liver","year":"2018","journal-title":"J. Hepatol."},{"issue":"13","key":"10.1016\/j.ejrad.2023.111120_b0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2023.111120_b0020","doi-asserted-by":"crossref","unstructured":"M. Seidensticker, O. \u00d6cal, K. Sch\u00fctte, P. Malfertheiner, T. Berg, C. Loewe, H.J. Kl\u00fcmpen, O. van Delden, M.R. \u00dcm\u00fctl\u00fc, N.B. Khaled, Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial, JHEP Reports (2023) 100699.","DOI":"10.1016\/j.jhepr.2023.100699"},{"key":"10.1016\/j.ejrad.2023.111120_b0025","first-page":"iv59-iv60","article-title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2","volume":"30","author":"Knox","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2023.111120_b0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejrad.2023.111120_b0035","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.ejrad.2023.111120_b0040","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jhep.2018.01.024","article-title":"Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma","volume":"68","author":"Kim","year":"2018","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejrad.2023.111120_b0045","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1148\/radiol.13120775","article-title":"Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker","volume":"267","author":"Choi","year":"2013","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.ejrad.2023.111120_b0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41416-021-01577-6","article-title":"Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma","volume":"126","author":"\u00d6cal","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ejrad.2023.111120_b0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","article-title":"Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial","volume":"3","author":"Vietti Violi","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejrad.2023.111120_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100173","article-title":"Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma","author":"Ricke","year":"2020","journal-title":"JHEP Reports"},{"issue":"6","key":"10.1016\/j.ejrad.2023.111120_b0065","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejrad.2023.111120_b0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","article-title":"A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma","volume":"245","author":"Lo","year":"2007","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/j.ejrad.2023.111120_b0075","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.24430","article-title":"Effect of vitamin K2 on the recurrence of hepatocellular carcinoma","volume":"54","author":"Yoshida","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejrad.2023.111120_b0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00535-014-0956-9","article-title":"Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study","volume":"50","author":"Okita","year":"2015","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ejrad.2023.111120_b0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000501501","article-title":"Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"15","key":"10.1016\/j.ejrad.2023.111120_b0090","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fon-2020-0162","article-title":"IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","volume":"16","author":"Hack","year":"2020","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2023.111120_b0095","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00261-021-03392-2","article-title":"The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma","volume":"47","author":"Yang","year":"2022","journal-title":"Abdom. Radiol. (NY)"},{"issue":"3","key":"10.1016\/j.ejrad.2023.111120_b0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.04.024","article-title":"Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma","volume":"67","author":"Lee","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejrad.2023.111120_b0105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejrad.2023.111120_b0110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejrad.2023.111120_b0115","doi-asserted-by":"crossref","unstructured":"O. \u00d6cal, K. Sch\u00fctte, J. Kup\u010dinskas, E. Morkunas, G. Jurkeviciute, E.N. de Toni, N. Ben Khaled, T. Berg, P. Malfertheiner, H.J. Kl\u00fcmpen, C. Sengel, B. Basu, J.W. Valle, J. Benckert, A. Gasbarrini, D. Palmer, R. Seidensticker, M. Wildgruber, B. Sangro, M. Pech, J. Ricke, M. Seidensticker, Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial, J. Cancer Res. Clin. Oncol. (2021).","DOI":"10.1007\/s00432-021-03627-1"},{"issue":"1","key":"10.1016\/j.ejrad.2023.111120_b0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00330-022-09000-1","article-title":"Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression","volume":"33","author":"\u00d6cal","year":"2023","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.ejrad.2023.111120_b0125","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejrad.2023.111120_b0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann. Surg."},{"issue":"10","key":"10.1016\/j.ejrad.2023.111120_b0135","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1245\/s10434-008-0043-7","article-title":"Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors","volume":"15","author":"Berber","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.ejrad.2023.111120_b0140","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/liv.14187","article-title":"Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system","volume":"39","author":"Lachenmayer","year":"2019","journal-title":"Liver Int."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X23004345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X23004345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:38:33Z","timestamp":1759995513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X23004345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"alternative-id":["S0720048X23004345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2023.111120","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2023.111120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111120"}}